BIXT— BIOXYTRAN, INC

Metric	FY2025	FY2024	FY2023	FY2022
Research and development	$454K+304.1%	$112K-90.2%	$1.1M+17.5%	$978K
General and administrative	$648K-44.5%	$1.2M-16.8%	$1.4M+50.3%	$934K
General and administrative affiliates	$740K-21.5%	$943K-24.4%	$1.2M	—
Total operating expenses	$1.8M-17.1%	$2.2M-41.5%	$3.8M+78.1%	$2.1M
Loss from operations	-$1.8M+17.1%	-$2.2M+41.5%	-$3.8M-78.1%	-$2.1M
Loss of issuance	$488K	—	-$212K	—
Change in FV of Derivative	-$217K-262.8%	$133K	—	—
Interest expense	-$134K-59.4%	-$84K+56.4%	-$193K+6.7%	-$207K
Interest expense affiliate	-$52K-522.0%	-$8K	—	—
Amortization of Intellectual Property	-$12K-45.2%	-$8K+4.0%	-$8K-127.4%	-$4K
Debt forgiveness	$134K	—	—	—
Debt discount amortization	-$678K	—	-$349K-11.6%	-$312K
Total other expenses	-$281K-78.8%	-$157K+79.4%	-$763K-45.8%	-$523K
Net loss before provision for income taxes	-$2.1M+10.8%	-$2.4M+47.8%	-$4.6M-71.7%	-$2.7M
Net loss	-$2.1M+10.8%	-$2.4M+47.8%	-$4.6M-71.7%	-$2.7M
Net loss attributable to the non-controlling interest	$13K	—	$90K-53.3%	$193K
NET LOSS ATTRIBUTABLE TO BIOXYTRAN	-$2.1M+10.3%	-$2.4M+47.1%	-$4.5M-81.5%	-$2.5M
Loss per common share, basic	-$0.02+0.0%	-$0.02+33.3%	-$0.03-50.0%	-$0.02
Loss per common share, diluted	-$0.02+0.0%	-$0.02+33.3%	-$0.03-50.0%	-$0.02
Weighted average number of common shares outstanding, basic	91.8M-33.7%	138.6M+3.5%	134.0M+16.4%	115.1M
Weighted average number of common shares outstanding, diluted	91.8M-33.7%	138.6M+3.5%	134.0M+16.4%	115.1M

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 12 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.